Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.48 |
| ▸ | HPGD | P15428 | 7/20 | 0.48 |
| ▸ | GAA | P10253 | 7/20 | 0.48 |
| ▸ | GLA | P06280 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 9/20 | 0.46 |
| ▸ | NPC1 | O15118 | 9/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL970079 | 0.94 | ALDH1A1 (0.49) | KDM4EALDH1A1HSD17B10HPGDGAA | |
| SCHEMBL969756 | 0.87 | RAB9A (0.54) | KDM4EALDH1A1HSD17B10HPGDGAA | |
| SCHEMBL969831 | 0.86 | RAB9A (0.53) | KDM4EALDH1A1HSD17B10HPGDGAA | |
| SCHEMBL970575 | 0.86 | RAB9A (0.53) | KDM4EALDH1A1HSD17B10HPGDGAA | |
| SCHEMBL2438451 | 0.83 | ALDH1A1 (0.48) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL1509768 | 0.82 | ALDH1A1 (0.45) | KDM4EALDH1A1HSD17B10HPGDGAA | |
| SCHEMBL970263 | 0.80 | KCNQ2 (0.56) | KDM4EALDH1A1HSD17B10HPGDGAA | |
| SCHEMBL30824695 | 0.80 | KCNQ2 (0.56) | KDM4EALDH1A1HSD17B10HPGDGAA | |
| SCHEMBL30794894 | 0.80 | LMNA (0.49) | KDM4EALDH1A1HSD17B10HPGDGAA | |
| SCHEMBL969661 | 0.80 | GBA1 (0.67) | KDM4EALDH1A1HSD17B10HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298766-B1 | Pharmaceutical formulations comrpising a substituted pyridine derivative | LUNDBECK & CO AS H (DK) | 2013-09-18 | — | — | EP | claimed |
| US-8299071-B2 | Substituted pyridine derivatives | H. LUNDBECK A/S (DK) | 2012-10-30 | — | — | US | claimed |
| EP-2298766-A1 | Substituted pyridine derivatives | H. Lundbeck A/S (DK) | 2011-03-23 | — | — | EP | claimed |
| US-20110003811-A1 | SUBSITUTED PYRIDINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2011-01-06 | — | — | US | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-8299071-B2 | Substituted pyridine derivatives | H. LUNDBECK A/S (DK) | 2012-10-30 | — | — | US | disclosed |
| EP-2298766-A1 | Substituted pyridine derivatives | H. Lundbeck A/S (DK) | 2011-03-23 | — | — | EP | disclosed |
| US-20110003811-A1 | SUBSITUTED PYRIDINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003811-A1 | SUBSITUTED PYRIDINE DERIVATIVES | KCNQ2, KCNQ1, KCNQ5 | KDM4E 666/4885ALDH1A1 2209/4885HSD17B10 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.